

Which Scale Up Strategies/Programmatic Mixes are most Cost-Effective?

Iris Semini
UNAIDS
May 2018

Outline

- Scaling up for Impact
- Critical Point of the Response
- Choices of strategies
- Accelerating Implementation
- Conclusions



TARGETS

By 2020

By 2030

90-90-90
HIV treatment

95-95-95
HIV treatment

500 000
New adult HIV infections


200 000
New adult HIV infections

ZERO
Discrimination


ZERO
Discrimination

Impact


NEW HIV INFECTIONS, 2000–2016



AIDS-RELATED DEATHS, 2000–2016




The platform: investing strategically to maximize impact



SYNERGIES WITH DEVELOPMENT SECTORS: Social protection, education, legal reform, gender equality, GBV, health and community systems, employer practices


Investment Approach: Combination of Interventions and Resource Needs by Intervention, 2013–2030.



Stover J, Bollinger L, Izazola JA, Loures L, DeLay P, et al. (2016) What Is Required to End the AIDS Epidemic as a Public Health Threat by 2030? The Cost and Impact of the Fast-Track Approach. PLOS ONE 11(5): e0154893. <https://doi.org/10.1371/journal.pone.0154893>
<http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0154893>


Investing for Impact: Fast Track the Response

NEW HIV INFECTIONS



Fast-Track: Scale up of all interventions to reach Fast-Track targets by 2020 (90-90-90 for ART, PMTCT, VMMC, condoms, key populations, PrEP, social enabling programs, opioid substitution therapy and cash transfers for girls).

NUMBER OF PEOPLE LIVING WITH HIV ON ANTIRETROVIRAL THERAPY, 2000–mid-2017, AND THE 2020 TARGET



90-90-90 treatment for all

The power of antiretroviral medicines

Saving lives
If antiretroviral therapy is initiated early and taken for life, life expectancy of people living with HIV is thought to be the same as that of someone without HIV.

Preventing mother-to-child transmission of HIV
Women living with HIV can improve their health and prevent their children from HIV infection by taking antiretroviral medicines during pregnancy and for the rest of their lives.

Post-exposure prophylaxis for averting HIV infection
A short course of antiretroviral therapy is effective for averting HIV infection caused by accidental exposure to HIV or exposure during unprotected sex.

Restoring respect and dignity to people living with HIV
Access to antiretroviral therapy has in some places reduced the stigma of HIV and lessened the discrimination people living with HIV face in many settings. HIV treatment has helped to normalize HIV, which is no longer considered a death sentence.

Reducing maternal mortality
Recent research has shown that the provision of antiretroviral therapy would avert much of the maternal mortality that occurs in the countries with a heavy HIV burden.

Preventing HIV transmission among serodiscordant couples
People who are living with HIV and achieve viral suppression have a lower risk of transmitting HIV to their uninfected sexual partner.

Reducing the number of children becoming orphans
As antiretroviral therapy increases the survival of adults, fewer children are becoming orphans. The burden of home-based care, which often fell on young girls, has declined and children are able to return to school.

Restoring employment
People receiving HIV treatment have regained their strength and good health, ending prolonged absenteeism from work.

Pre-exposure prophylaxis for people at higher risk
People who are at higher risk of acquiring HIV can lower this risk by taking a combination of antiretroviral medicines as a pre-exposure prophylaxis.


Preventing tuberculosis (TB), TB-related deaths and TB transmission
People who are living with HIV and taking HIV treatment lower their risk of developing TB disease. Antiretroviral medicines improve the effectiveness of TB treatment, reduce TB-related mortality and cut the risk of transmitting TB to others.


Increasing Evidence on What Works

Intervention	Effect	Effect size	Cost
ART:			
• Community adherence	Increase adherence	50% reduction	
• Home-based ART	Increase ART uptake	RR = 2.75	
• Adherence clubs	Reduce drop-outs	HR = 0.43	
	Increase adherence	HR = 0.33	
• CHW promote adherence	Increase adherence	OR = 1.22	
• mHealth	Increase adherence	RR = 0.77	\$20/p/y
HTC:			
• Partner testing	Increase uptake	Double	
• Community testing	Increase uptake	Triple	
• Workplace testing	Increase uptake	RR = 2.8	\$8-\$33 per person
Sex workers:			
• Community empowerment	Increase condom use	OR = 3.27	\$80/p/y for community empowerment
• Violence prevention	Increase condom use	OR = 1.49	
PMTCT			
• Option B+	Reduce MTCT rate	Reduce from 8.6% to 4.9%	
Critical enablers			
• Cash transfers	Reduce number of partners	25%	
• Mass media	Delay sexual debut	1 year delay	
• School AIDS education	Increase condom use	15%	
• Community mobilization	Delay sexual debut	1 year delay	
	Increase condom use	20%	\$2/student/year
	Increase condom use	11%	\$5/person/year


2016 Namibia Investment Case: Invest on HIV response for better health

- Investments on HIV response have improved health outcomes
- Cost – Effective: HIV response prevents a death at a cost of about US\$ 20,000, or a cost per life year saved at about US\$ 1,000 - one-sixth of GDP per capita
- Behavior change and the public ART program has been an investment in social equity: providing access to those who would have not benefited if public investments on HIV response were not made





SOUTH AFRICAN HIV AND TB INVESTMENT CASE
REFERENCE REPORT



Interventions, efficiency factors, enablers and synergies suggested by stakeholder consultation

Available evidence (working groups)

Good quality of evidence (working groups/ consultants)

Good quality of evidence (modellers); ability to be modelled

- 24 HIV interventions, 3 TB intervention groups
- 9 efficiency factors
- 13 enablers and development synergies



What combination of interventions will give the highest impact?

South Africa Investment Case: Rigorous Selection of Interventions

Intervention	
Condom availability (90%)	AFFORDABLE UNDER CURRENT BUDGET
MMC (90%)	
SBCC campaign 1 (90%)	
MMC age group targeting	
Testing at 6 weeks (90%)	
ART at current guidelines (85%)	
PMTCT B+ (60%)	90/90/90 TARGETS
HCT (90%)	
SBCC campaign 3 (90%)	
Universal test and treat (90%)	

Budget in 2016/17
ZAR 21.7 billion

- ### Critical enablers
- Community-based GBV intervention (SASA!)
 - HIV prevention for alcohol and drug users
 - Alcohol counselling in STI clinics
 - Parental monitoring
 - School feeding
 - Positive parenting
 - Teacher support


- ### Synergies
- Pharmacovigilance
 - Supply chain reforms
 - Supporting orphan girls to stay in school
 - School based HIV/STI risk reduction
 - State-provided child-focused cash transfers
 - Vocational training for adolescent girls

- ### Enablers that are part of baseline
- NIMART (80% coverage by 2016/17)
 - Defaulter tracers, SMS systems
 - Community mobilisation/ demand creation for almost all interventions (MMC, HCT, PrEP, microbicides)
 - Included SBCC as interventions

- ### ART efficiency factors
- Adherence clubs
 - Home-based ART
 - Point-of-care CD4
 - GP down referral
 - Community-based adherence supporters

- ### HCT efficiency factors
- Mobile HCT
 - Home-based HCT
 - Workplace HCT
 - PICT
 - HCT invitations to pregnancy partners




South Africa HIV and TB Investment Case, 2016




Government Policy is already efficient but it can be improved:

- Increase condom availability
- Increase access to male medical circumcision
- Implement social behavior change as part of the program interventions
- Increase HIV testing uptake for adolescent
- Use the money saved to scale up ART

Impact on HIV Epidemic: 2016 Namibia Investment Case






*Critical Point of
the Response*




REDUCTIONS IN NEW INFECTIONS ARE OFF TARGET



Source: UNAIDS 2017 estimates

TREATMENT CASCADE PROGRESS VARIES AMONG REGIONS



KNOWLEDGE OF HIV STATUS, TREATMENT COVERAGE AND VIRAL LOAD SUPPRESSION, BY REGION, 2016

Comparison of HIV testing and treatment cascades by region reveals different patterns of progress. Western and central Europe and North America are approaching global targets. Latin America and eastern and southern Africa show high levels of achievement across the cascade. Eastern Europe and central Asia, the Middle East and North Africa, and western and central Africa are clearly on track.

Source: UNAIDS special analysis, 2017; see annex on methods for more details.

¹ Cascade for the western and central Europe and North America region is for 2015.

SLOWING SCALE-UP OF PAEDIATRIC TREATMENT




FIGURE 3.13. NUMBER OF CHILDREN AGED 0-14 YEARS ACCESSING ANTIRETROVIRAL THERAPY, GLOBAL, 2000-2016 PLUS 2018 TARGET

Source: UNAIDS 2017 estimates. Global AIDS Monitoring, 2017.

TREATMENT COVERAGE LOWER AMONG MEN





FIGURE 3.17. ANTIRETROVIRAL THERAPY COVERAGE AMONG ADULTS LIVING WITH HIV AGED 15 YEARS AND OLDER, BY SEX, BY REGION, 2016

Source: Global AIDS Monitoring, 2017. UNAIDS 2017 estimates.

Focus on Young People

Progress to 90/90/90 in 15 to 24 year olds




Note: Results based on self-report of HIV awareness and ART status (plus ARV testing in Malawi and Zambia), and on viral load testing.

Source: PEPFAR PHIA


Adolescent Girls and Young Women

Swaziland Trends: HIV Prevalence Among Women 18-49 Years by Age, SHIMS 1 (2011) vs. SHIMS 2 (2016-17)



Source: Swaziland PHIA

Key Populations



DISTRIBUTION OF NEW HIV INFECTIONS, BY POPULATION, GLOBAL, SUB-SAHARAN AFRICA AND COUNTRIES OUTSIDE OF SUB-SAHARAN AFRICA, 2015

Source: UNAIDS special analysis, 2017.

*Only reflects Asia and the Pacific, Latin America and Caribbean regions.

Stigma

- A major barrier to access services across countries
- Key Elements of stigma identified along the prevention and the treatment cascade
- Stigma in the healthcare setting is pervasive

Scaling up for Impact?

- We are at a critical point of the response – a people centred approach
- The Investment Approach application is relevant: it is a combination of programme package with interventions that address barriers that will have the highest impact
- Data: Mapping the gaps will require granular analysis of who is left behind, why is left behind
- Geography and Population: young people, key populations, men
- Combination of interventions that will give the highest impact for that particular gap to be developed and implemented with communities
- Accelerate Quality Implementation: policies that remove barriers to services, resources and adapt quickly to epidemic dynamic and response

VMMC

- Cost-effective
- Targeted to young men
- 14 countries

VOLUNTARY MEDICAL MALE CIRCUMCISION NEEDS A BOOST IN KEY COUNTRIES





FIGURE 5.5. PREVALENCE OF MALE CIRCUMCISION (AGED 15-49), 14 PRIORITY COUNTRIES, 2005-2015


Source: Population-based surveys, 2005-2015.

350,000 New Infections among girls & young women, 15-24 years, in 2015

More than two-third occur in Eastern and Southern Africa




A response targeted to the cycle of transmission



Empower the young women and girls

15 million adolescent girls have experienced sexual violence

- Early sexual debut and sexual violence are associated with each other and with risk for HIV
- Address Gender-based violence
- Education has positive impact



Percentage distribution of girls aged 15 to 19 years who ever experienced forced sex, by age at first incident

Notes: These data need to be interpreted with caution since there are significant proportions of girls who could not recall the exact age at which they first experienced forced sex and of missing data overall in many countries. Only those countries where the proportion of 'don't know/missing' was less than 20% are included in the chart. Data for Comoros, Ethiopia and Kenya are based on 25 to 49 unweighted cases.

Source: UNICEF global databases, 2017, based on DHS, 2005–2016.

Community-mobilization approaches work

- **SASA!** - “NOW” – Kampala, Uganda

Community mobilization intervention to reduce:

- attitudes towards gender roles and norms
 - levels of intimate-partner violence (IPV)
 - HIV-related behaviours
 - community responses to violence against women.
-
- The primary trial outcome: experience of physical IPV with an estimated 1201 cases averted (90 % CI: 97–2307 cases averted).
 - The estimated cost per case of past year IPV averted was US\$460.




Source: Strive Consortium

PrEP

- **Targeted** : Since 2015, PrEP is recommended by the WHO for populations at ‘substantial risk’ of HIV
- From efficacy trials to implementation requires to adapt interventions

STUDY AND POPULATION	PROTECTIVE EFFECT OF PREP-ALL STUDY PARTICIPANTS	PROTECTIVE EFFECT AMONG PARTICIPANTS WITH HIGHER ADHERENCE
Heterosexual men and women (Partners PrEP ⁵ ; TDF-2 study ⁶): Botswana, Kenya and Uganda	62% – 76%	Up to 90%
Gay men and other men who have sex with men (iPrEX study ⁷): Brazil, Ecuador, Peru, South Africa, Thailand and the United States	44%	90%
People who inject drugs (Bangkok Tenofovir Study ⁸)	49%	75%
FEM-PrEP ⁹ : heterosexual women in Kenya, South Africa and the United Republic of Tanzania	<30% adherence, no effect	<30% adherence, no effect
VOICE ¹⁰ heterosexual women in South Africa, Uganda and Zimbabwe	<30% adherence, no effect	<30% adherence, no effect

Declining Epidemic Trends in San Francisco: likely PrEP contribution



Adapted from SF DPH, HIV Epidemiology Annual Report, 2016


The number of people using PrEP to prevent HIV is now thought to have risen to around 120 000 people, the majority in the United States of America.

PrEP

- Rolling out oral PrEP progressively to broader sub-populations based on risk and geography affect the impact, cost-effectiveness, and total cost of the programme
- The impact, cost, and cost-effectiveness vary by risk group (FSW, SDCs, MSM, PWID, AGYW, AM)
- Varying unit cost of oral PrEP by risk group affect the impact and cost-effectiveness of oral PrEP
- Level of adherence by risk group would affect the impact and CEA of oral PrEP

Source: HP+/Project SOAR Oral PrEP Modeling, January 2018


Cost-Effectiveness, HIV Infections Averted, and Total Cost of PrEP Program by Risk Group, 2018-2030



-Bubble size and data labels: Total cost of adding PrEP program, USD millions

Illustrative Modelling in a high prevalence country – assume that the country achieves 90-90-90

Policies: Availability of pre-exposure prophylaxis, by country, 2017



■ Regulatory approval, framework** being put in place, PrEP use csaling up*

■ No regulatory approval; reported low-level off-label PrEP use

■ Regulatory approval, but any PrEP use is private


■ PrEP not available

■ Demonstration project


■ No data

Policies Matter: The negative Impact of User Fees

Coverage of pregnant women who receive ARV for PMTCT - by region



Source: UNAIDS Estimates 2017; Global AIDS Monitoring 2017



No PMTCT

Testing – achieving the first '90

Poster # 887 **ADVANCED HIV AND THE CARE CASCADE IN THE BOTSWANA COMBINATION PREVENTION PROJECT**

R Lebelonyane¹, L Mills², C Mgorosi³, H Wang³, T Marukutira³, J Theu³, M Kapanda¹, S Matambo², S El-Halabi¹, J Moore⁴, L Block⁵, J Makhema⁶, E Kadima⁶, P Bachanas⁴, J N Jarvis^{2,6,7}

1. Botswana Ministry of Health, Gaborone, Botswana, 2. Centers for Disease Control and Prevention, Gaborone, Botswana, 3. Northrop Grumman, Atlanta, GA, 4. Centers for Disease Control and Prevention, Division of Global HIV/AIDS and TB, Atlanta, GA, 5. Intellectual Concepts, Atlanta, GA, 6. Botswana-Harvard Partnership, Gaborone, Botswana, 7. Botswana-University of Pennsylvania Partnership, Gaborone, Botswana

BACKGROUND

Individuals starting antiretroviral treatment (ART) with advanced HIV-disease (defined by the WHO as CD4 count <200 cells/μL) may have higher rates of early attrition from care due to HIV-related morbidity and mortality.

We determined the burden of advanced HIV-disease in community residents not already taking ART, and evaluated the impact of advanced HIV disease on treatment linkage and retention in a routine clinical setting in Botswana.

METHODS

The Botswana Combination Prevention Project (BCPP) is a cluster-randomized trial evaluating the impact of a combination prevention package on HIV incidence in 30 rural and semi-urban communities in Botswana.

This sub-analysis of the 15 intervention communities compares rates of:

- linkage to care,
- ART initiation,
- retention in care, and
- virological suppression

in patients identified through community testing between November 2013 and May 2016 with CD4 counts <200 cells/μL versus those with CD4 counts >200 cells/μL.


During this period all individuals had a PMA point of care CD4 in the community at the time of community testing.

Patients were eligible for ART if CD4 counts were <500 cells/μL or viral load >10,000 copies/ml. Data were censored at the end of November 2017.

RESULTS

BCPP assessed HIV status in 44,223 individuals; 10,359 (23%) were HIV-infected, 2,706 (26%) of whom were not on ART and were referred for HIV care. Of the 2,569 who had a point-of-care CD4 test, 521 (20%) had CD4 <200 cells/μL.

Men were more likely to have a CD4 count <200 cells/μL (24% of men vs 18% of women, OR 1.4, 95% CI 1.1-1.8). The median



CONCLUSIONS

Twenty percent of HIV-infected individuals not on ART in the community had advanced HIV-disease (CD4 <200 cells/μL).

The proportion of community residents not on ART with advanced HIV-disease did not decline over time despite linkage activities.

Advanced HIV-disease had lower rates of linkage to care, lower rates of ART initiation, lower levels of retention, and higher mortality compared to non-advanced HIV-disease.

These findings highlight the need to focus efforts on linkage to care of all HIV-infected persons, as well as strategies to support individuals with advanced HIV-disease to ensure rapid linkage to ART initiation, and good retention in care in the population.

Botswana

1 in 5 people in community not on ART had advanced HIV disease

Initiated ART (≥6 months ago)	Retained in Care	Had a viral Load Test	Viral Suppression (<400)
1,375	1,286 (93%)	1,259 (98%)	1,250 (99%)
429	391 (91%)	375 (96%)	369 (98%)

*All timings from time of study HIV testing
 **At time of data censoring in November 2017. At this time point 492 (94%) with CD4 <200 cells/μL and 1,551 (96%) with CD4 >200 cells/μL had initiated ART (p<0.05); 463 (97%) with CD4 <200 cells/μL and 1,443 (90%) with CD4 >200 cells/μL had initiated ART (p<0.05); and 409 (79%) with CD4 <200 cells/μL and 1,368 (85%) with CD4 >200 cells/μL were retained in care (p<0.001).

THE HIV TESTING AND TREATMENT CASCADE




FIGURE 3.4. KNOWLEDGE OF HIV STATUS, TREATMENT COVERAGE AND VIRAL LOAD SUPPRESSION, GLOBAL, 2016

Source: UNAIDS special analysis, 2017; see annex on methods for more details.

Testing – achieving the first '90

- Several testing modalities that need to be targeted/selected and implemented driven by **specific epidemiology and barriers to access – who is not tested**
- Traditionally fragmented HTC models vs an integrated HTS model
- Ensure quality rapid HIV testing service delivery with accurate results
- Develop tools to support testing for partners and family of index patients
- Testing for key populations is part of the package tailored to their needs
- Explore innovative approaches for **reaching young people, and men with HIV self-testing, multi-disease campaigns, and targeting male-friendly venues**

Linkages: HIV self-testing and PrEP

Be Self Sure - Kenya

Kenya launches self-test kit and PrEP

Effect of HIV self-testing on sexual partner numbers for Zambian female sex workers*

- No effect (increase or decrease) on condom use.
- Evidence was based on self-report, but findings similar to previous findings that HIVST does not increase sexual risk behaviours
- Suggests that HIVST may have additional benefits – esp with regular partners.

*Oldenburg et al.2018. (Katz 2015; Jamil 2017;Wang 2017)

Better testing in ANC - & maybe reaching out men?

Female HIV acquisition per sex act is elevated in late pregnancy/postpartum

Reproductive Stage	Base Model*		Adjusted Model**	
	RR (95% CI)	p-value	RR (95% CI)	p-value
Non-pregnant / postpartum	1.00	--	1.00	--
Early pregnancy through postpartum	4.97 (2.95, 8.38)	<0.001	2.76 (1.58, 4.81)	<0.001
Early pregnancy	3.20 (1.24, 8.25)	0.02	2.07 (0.78, 5.49)	0.14
Late pregnancy	5.54 (2.62, 11.69)	<0.001	2.82 (1.29, 6.15)	0.01
Postpartum	7.80 (3.04, 20.02)	<0.001	3.97 (1.50, 10.51)	0.01

*Adjusted for condom use, reproductive stage
 **Adjusted for condom use, reproductive stage female age, active PrEP use, HIV RNA of



UNIVERSITY OF WASHINGTON
 INTERNATIONAL CENTER FOR AIDS AND HIV RESEARCH

Heffron et al Partners in Prevention HSV/HIV Transmission Study abstract #



Repeat HIV testing during pregnancy in Kenya: an economic evaluation

Rogers et al abstract #1147

- Late pregnancy repeat HIV testing cost effective in Kenyan \$1,098/QALY - 757 averted perinatal HIV transmissions and 208 reduced maternal and child deaths.
- Model did not consider potential horizontal HIV transmissions averted, use of additional interventions during labour to reduce transmission. These omissions possibly rendered estimates conservative.

In higher incidence settings greater benefit likely

Community-based approaches work

Impact of community-based HIVST distribution on demand for ART in Zimbabwe

Data from 144 ART clinics


- 40 serving the 38 HIVST communities (3,138 initiations)
- 124 comparison (9,670 initiations)

Difference-in-differences in rate of ART initiation by HIVST in catchment area

During HIVST: Adj. RR 1.27 (1.14-1.43)

After HIVST: Adj. RR 1.00 (0.87-1.15)

Sibanda et al abstract #150LB




Key Populations

Proven Approaches for Key Populations

Target by 2020
90% Access to Tailored
Prevention and
Treatment Services

Acceptability of
services is a key
element for
effectiveness
innovative,

Tailored, **community-
led approaches**




Scale Matters


National trends in HIV prevalence in 3 KP in Ukraine

Pooled analysis of 4 nationally-representative IBBS surveys → confirmed the decreasing trend in HIV prevalence in PWID and FSW, suggesting:

- ↓PWID HIV due to "massive harm reduction program" supported by GF covering >60% of est PWID nationally
- ↓ in FSW HIV also due to prevention coverage
- recent increase in MSM, esp younger subgroup, may indicate a new wave of non-injection related transmission



Systematic scale up: India Sex Worker program



- National leadership
- More than 150 implementing Community Based Organizations
- Supportive monthly supervision and mentoring;
- Intensive 3-days onsite visits each month to review implementation
- Quarterly grading of implementers

PrEP and early ART for female sex workers in South Africa

PrEP for HIV-negative SWs; early ART for HIV-positive SWs.

- 947 SWs seen in clinic → 692 were HIV tested → HIV prevalence 49%.
- Among those returning to clinic after testing and confirmed clinical eligibility
 - 98% took PrEP (219/224) – 22% seen at 12m
 - 94% (139/148) early ART - 60% seen at 12m
- Little change in consistent condom use or # sex partners (high levels condom use with clients; low use with main partners)
- No seroconversions on PrEP; 7 virological failures on early ART
- Total cost of service delivery \$126 for PrEP and \$406 for early ART per person-year

TREAT ALL

High Coverage of ART Associated with Decline in Risk of HIV Acquisition in Rural KwaZulu-Natal, South Africa

Frank Tanser,^{1*} Till Bärnighausen,^{1,2} Erofilo Grapsa,¹ Jaffer Zaidi,¹ Marie-Louise Newell^{1,3}

Science

THE LANCET
Global Health

Use of antiretroviral therapy in households and risk of HIV acquisition in rural KwaZulu-Natal, South Africa, 2004–12: a prospective cohort study

Alain Vandormael, Marie-Louise Newell, Till Bärnighausen, Frank Tanser

Antiretroviral Therapy to Prevent HIV Acquisition in Serodiscordant Couples in a Hyperendemic Community in Rural South Africa


Catherine E. Oldenburg ✉, Till Bärnighausen, Frank Tanser, Collins C. Iwuji, Victor De Gruttola, George R. Seage, III, Matthew J. Mimiaga, Kenneth H. Mayer, Deenan Pillay, Guy Harling

Clinical Infectious Diseases




Test and Treat all

Test and treat in Uganda



Test and treat quarterly trend in Zambia




the number of people newly initiating HIV treatment increase from 23 000 in the first quarter of 2016 to 45 000 in the final quarter of 2017


Combination of Interventions will make the greater impact

HIV Incidence and Prevalence in the Rakai Community Cohort Study, 1999–2016

A Men and Women




B Viral-Load Suppression among HIV-Positive Persons



Grabowski MK et al. *N Engl J Med* 2017;377:2154-2166.

Countries adopting the Treat All Policy




- Treat all regardless of CD4 count
- CD4 count of 500 cells/mm³ or less
- CD4 count of 350 cells/mm³ or less
- No data

Human Rights


- The cornerstone of removing legal barriers
- Important and essential at any context of the epidemic
- Broad options to explore the legal barriers (human right assessment) and tools to address in a tailored way adapted to country context

Resource Availability Falling Short of Needs



Investing for Impact

- We are at a critical point and smart investments and rapid quality implementation are urgently needed
- Adult new infections declining too slowly
- **Investment Approach:** a combination of programme interventions combined with those that address the barriers, in particular stigma and human rights, delivered in partnership with communities
- Data and targeted combination of interventions + treat all
- Accelerate implementation: from pilots to scale
- The core policies are adopted quick and continuously evolving
- The response should be dynamic and leverage synergies at multiple level synergistically on multiple levels – individual, family and society
- Flexible – adapts to changing epidemic patterns and can rapidly deploy innovations





Invest for a People Centered Approach

